Your browser doesn't support javascript.
loading
Value and level of galectin-3 in acute myocardial infarction patients undergoing primary percutaneous coronary intervention.
Tsai, Tzu-Hsien; Sung, Pei-Hsun; Chang, Li-Teh; Sun, Cheuk-Kwan; Yeh, Kuo-Ho; Chung, Sheng-Ying; Chua, Sarah; Chen, Yung-Lung; Wu, Chiung-Jen; Chang, Hsuen-Wen; Ko, Sheung-Fat; Yip, Hon-Kan.
Afiliação
  • Tsai TH; Division of Cardiology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan.
J Atheroscler Thromb ; 19(12): 1073-82, 2012.
Article em En | MEDLINE | ID: mdl-23037954
AIM: This study investigated the impact of the circulating galectin-3 level on the 30-day prognostic outcome in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). METHODS: From May 2009 to March 2011, blood samples for assessment of the circulating galectin-3 level were collected from 196 consecutive STEMI patients treated by primary PCI and from 30 healthy volunteers. RESULTS: The galectin-3 level was determined using ELISA. Our results demonstrated that the circulating level of galectin-3 was significantly higher in STEMI patients than in healthy control subjects (p<0.001). As compared with patients with galectin-3 <7.67 ng/mL, patients with galectin-3 ≥7.67 ng/mL were significantly older, had significantly lower left ventricular ejection fraction and significantly higher frequency of elevated white blood cell count, advanced Killip score (defined as ≥ score 3), congestive heart failure (defined as ≥ New York Heart Association Functional Class III), respiratory failure, unstable hemodynamics requiring a mechanical ventilator and intra-aortic balloon pump support, multiple vessel diseases and 30-day mortality (all p<0.04). Furthermore, multivariate analysis showed that elevated circulating level of galectin-3 was the strongest independent predictor of the combined 30-day major adverse clinical outcome (MACO) (defined as advanced CHF or 30-day mortality) (p<0.0001). CONCLUSION: A high circulating galectin-3 level may serve as a useful biomarker for predicting 30-day MACO in patients with STEMI undergoing primary PCI.
Assuntos
Buscar no Google
Base de dados: MEDLINE Assunto principal: Galectina 3 / Intervenção Coronária Percutânea / Infarto do Miocárdio Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2012 Tipo de documento: Article
Buscar no Google
Base de dados: MEDLINE Assunto principal: Galectina 3 / Intervenção Coronária Percutânea / Infarto do Miocárdio Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2012 Tipo de documento: Article